Benzinga | Apr 16, 2021 10:02AM EDT

AIkido Pharma Notes Advancement In Radiopharmaceutical Research; Co Highlights Study Announcing Early Results From PSMA 617-Lu177 Study

AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today noted that a recent study announced positive early results from a PSMA 617-Lu177 study conducted by a leading global pharmaceutical company. The report provides strong indications for analogous success in similar technology the Company is helping to develop.

The article can be accessed at:

https://www.thepharmaletter.com/article/further-vindication-for-novartis-in-radioligand-space

Anthony Hayes, CEO of AIkido Pharma, stated, "As a rising tide lifts all boats, these results indicate the strength of our prior investment in this technology field. These early reports indicate there is strong evidence that developing radioligand therapies have the potential to be an alternative cancer treatment and provide positive outcomes for patients with advanced prostate cancer. The Company's stock price has been down recently, but we believe these positive results from the Novartis Phase III study provides an incremental proof point that reinforces our confidence in the radiopharmaceutical space, PSMA and our investment in this technology. With testing data for our technology expected in Q2 of this year, we are excited about the results and the advancement of this technology."